Article Details
Retrieved on: 2024-11-03 10:28:00
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article outlines unmet needs in treating kidney diseases like primary membranous nephropathy (PMN) and the potential of biopharma innovations, such as monoclonal antibodies by firms like Novartis and MorphoSys, in addressing these.
Article found on: clarivate.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here